A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
about
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@ast
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@en
type
label
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@ast
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@en
prefLabel
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@ast
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@en
P2093
P2860
P921
P356
P1476
A phase 1/2 trial of ublituxim ...... eviously exposed to rituximab.
@en
P2093
Ahmed Sawas
Changchun Deng
Charles M Farber
Daruka Mahadevan
Hari P Miskin
Jennifer E Amengual
Jill M Kolesar
John G Kuhn
Marshall T Schreeder
Mazen Y Khalil
P2860
P304
P356
10.1111/BJH.14534
P407
P577
2017-02-21T00:00:00Z